drugset / Trial / NCT07101705
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Phase 0
Recruiting
40 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OriCell Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory hematological malignancies.
Timeline
- Start
- 2025-09-08
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OriV508 | Unknown | — | Intravenous |